Stocks Health care ICCC

NASDAQ · Health care

Immucell Corp (ICCC)

Immucell Corp brought in $30.7M of revenue over the twelve months to June 30, 2026, up 8.5% from a year earlier. Net income was $787.4K, a net margin of 2.6%. Operating cash flow minus capital spending left $1.2M of free cash flow in fiscal 2025. At June 30, 2026 it held $8.9M in cash against $8.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Watch ICCC in 60 seconds

Follow ICCC

Free, no password. An email when ICCC files with the SEC.

Key facts about Immucell Corp

Net worth

Immucell Corp has a market value (market cap) of $92.8M at the latest share price, and shareholders' equity of $31.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2025 revenue was $27.6M (+4.3% year on year), with a net loss of $1M. Over the 12 months to June 30, 2026: revenue $30.7M, net income $787.4K.

Cash flow

In fiscal 2025 operations brought in $2.5M of cash; after $1.3M of capital spending, free cash flow was $1.2M.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

What Immucell Corp does

Immucell Corp is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker ICCC.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where ICCC ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Immucell Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 13, 2026
   Quarterly report 10-Q · period to June 30, 2026Revenue rose 12% to $7.2M versus the same quarter last year; diluted EPS $0.20 versus $0.06.
2. August 13, 2026
   Quarterly results 8-K
3. July 9, 2026
   Quarterly results 8-K
4. June 17, 2026
   Shareholder vote results 8-K
5. June 10, 2026
   Investor disclosure 8-K
6. May 14, 2026
   Quarterly results 8-K
7. May 14, 2026
   Quarterly report 10-Q · period to March 31, 2026Revenue rose 28% to $10.4M versus the same quarter last year; diluted EPS $0.21 versus $0.16.
8. May 13, 2026
   Annual report (amended) 10-K/A · period to December 31, 2025Revenue rose 4.3% to $27.6M versus the prior year; diluted EPS -$0.12 versus -$0.26.
9. May 8, 2026
   Material agreement 8-K
10. April 24, 2026
    Proxy statement DEF 14A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 22, 2026. Insider transactions on SEC

What is ICCC worth? A DCF from its reported cash flow

Insider trades

What the people running Immucell Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns ICCC

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

3 insiders reported holding 290,683 shares in total, about $3M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ICCC

What does Immucell Corp do?

Immucell Corp is a company in the Health care sector, listed on NASDAQ as ICCC. Its shares trade on NASDAQ under the ticker ICCC.

What is Immucell Corp's net worth?

Immucell Corp has a market value (market cap) of $92.8M at the latest share price, and shareholders' equity of $31.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Immucell Corp profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $787.4K on revenue of $30.7M, a net margin of 2.6%.

How much revenue does Immucell Corp make?

Over the twelve months to June 30, 2026 Immucell Corp reported revenue of $30.7M. That is 8.5% more than a year earlier.

When did Immucell Corp last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026.

Similar companies

Compare ICCC with

Compare ICCC with any company

Follow ICCC

Get an email when Immucell Corp files with the SEC: results, executive changes, material agreements and annual reports.

Follow ICCC

Free, no password. An email when ICCC files with the SEC.

Where the numbers come from

Financial figures are the values Immucell Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.